Memantine for lewy body disorders: Systematic review and meta-analysis

American Journal of Geriatric Psychiatry

Volumn 23, Issue 4, 2015, Pages 373-383

  Matsunaga, Shinji ^a,b   Kishi, Taro ^a   Iwata, Nakao ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Okehazama Hospital   (Japan)

Author keywords

Lewy body disorders; Memantine; meta analysis; systematic review

Indexed keywords

LEVODOPA; MEMANTINE; PLACEBO; AMINO ACID RECEPTOR BLOCKING AGENT;

ASSESSMENT OF HUMANS; CEREBROVASCULAR ACCIDENT; CONFUSION; DAILY LIFE ACTIVITY; DIFFUSE LEWY BODY DISEASE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HUMAN; META ANALYSIS; MINI MENTAL STATE EXAMINATION; MOTOR PERFORMANCE; NEUROPSYCHIATRIC INVENTORY SCORE; OPEN STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCORING SYSTEM; SOMNOLENCE; SYSTEMATIC REVIEW; VERTIGO; LEWY BODY DISEASE; PATIENT DROPOUTS; STATISTICS AND NUMERICAL DATA;

EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; LEWY BODY DISEASE; MEMANTINE; PATIENT DROPOUTS;

EID: 84928035828     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1016/j.jagp.2013.11.007     Document Type: Article

References (33)

1. Yamawaki M, Kusumi M, Kowa H, et al: Changes in prevalence and incidence of Parkinson's disease in Japan during a quarter of a century. Neuroepidemiology 2009; 32:263e269
2. Hoegh M, Ibrahim AK, Chibnall J, et al: Prevalence of Parkinson disease and Parkinson disease dementia in community nursing homes. Am J Geriatr Psychiatry 2013; 21:529e535
3. Lippa CF, Duda JE, Grossman M, et al: DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007; 68:812e819
4. Kishi T, Iwata N: NMDA receptor antagonists interventions in schizophrenia: meta-Analysis of randomized, placebo-controlled trials. J Psych Res 2013; 47:1143e1149
5. Berman K, Brodaty H, Withall A, et al: Pharmacologic treatment of apathy in dementia. Am J Geriatr Psychiatry 2012; 20: 104e122
6. Danysz W, Parsons CG: The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry 2003; 18:S23-S32
7. Dalfo E, Albasanz JL, Martin M, et al: Abnormal metabotropic glutamate receptor expression and signaling in the cerebral cortex in diffuse Lewy body disease is associated with irregular alpha-synuclein/phospholipase C (PLCbeta1) interactions. Brain Pathol 2004; 14:388e398
8. Starr MS: Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse 1995; 19:264e293
9. Kucheryanu VG, Kryzhanovskii GN: Effect of glutamate and antagonists of N-methyl-D-Aspartate receptors on experimental parkinsonian syndrome in rats. Bull Exp Biol Med 2000; 130: 629e632
10. Aarsland D, Ballard C, Walker Z, et al: Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009; 8:613e618
11. Emre M, Tsolaki M, Bonuccelli U, et al: Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9:969e977
12. Leroi I, Overshott R, Byrne EJ, et al: Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Move Dis 2009; 24:1217e1221
13. Li W, Zhao JH, Sun SG, et al: Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson's disease [In Chinese]. Zhonghua yi xue za zhi 2011; 91:301e303
14. Merello M, Nouzeilles MI, Cammarota A, et al: Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin Neuropharmacol 1999; 22: 273e276
15. Ondo WG, Shinawi L, Davidson A, et al: Memantine for nonmotor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial. Parkinson Relat Dis 2011; 17: 156e159
16. Moreau C, Delval A, Tiffreau V, et al: Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebocontrolled pilot study. J Neurol Neurosurg Psychiatry 2013; 84: 552e555
17. Schneider LS, Olin JT, Doody RS, et al: Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheim Dis Assoc Dis 1997; 11(suppl 2):S22-S32
18. Olin JT, Schneider LS, Doody RS, et al: Clinical evaluation of global change in Alzheimer's disease: identifying consensus. J Geriatr Psych Neurol 1996; 9:176e180
19. Folstein MF, Folstein SE, McHugh PR: "Mini-Mental State." A practical method for grading the cognitive state of patients for the clinician. J Psych Res 1975; 12:189e198
20. Cummings JL, Mega M, Gray K, et al: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44:2308e2314
21. Gelinas I, Gauthier L, McIntyre M, et al: Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther 1999; 53: 471e481
22. Galasko D, Bennett D, Sano M, et al: An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheim Dis Assoc Dis 1997; 11(suppl 2):S33-S39
23. Cohn LD, Becker BJ: How meta-Analysis increases statistical power. Psychol Methods 2003; 8:243e253
24. DerSimonian R, Laird N: Meta-Analysis in clinical trials. Control Clin Trials 1986; 7:177e188
25. Moher D, Liberati A, Tetzlaff J, et al: Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA statement. BMJ 2009; 339:b2535
26. Ramaker C, Marinus J, Stiggelbout AM, et al: Systematic evaluation of rating scales for impairment and disability in Parkinson's disease. Move Dis 2002; 17:867e876
27. Fahn S, Elton R, Members of the UPDRS Development Committee. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease. Florham Park, NJ, Macmillan Healthcare Information, 1987, pp 153e164
28. Ballard C, McKeith I, Burn D, et al: The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering from dementia with Lewy bodies. Acta Neurol Scand 1997; 96: 366e371
29. Higgins JP, Thompson SG, Deeks JJ, et al: Measuring inconsistency in meta-Analyses. BMJ 2003; 327:557e560
30. Mantel N, HaenszelW: Statistical aspects of the analysis of data from retrospective studies of disease. JNatlCancer Inst 1959; 22:719e748
31. Weintraub D: Neuropsychiatric symptoms in Parkinson disease and dementia with Lewy bodies: what geriatric psychiatry can learn. Am J Geriatr Psychiatry 2013; 21:497e500
32. Donaghy P, Thomas AJ, O'Brien JT: Amyloid PET imaging in Lewy body disorders. Am J Geriatr Psychiatry 2015; 23:23e37
33. Boada M, Arranz FJ: Transdermal is better than oral: observational research of the satisfaction of caregivers of patients with Alzheimer's disease treated with rivastigmine. Dement Geriatr Cogn Dis 2013; 35:23e33